Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Orchestra BioMed Holdings's annualized net income for the quarter that ended in Jun. 2026 was $-95.02 Mil. Orchestra BioMed Holdings's average shareholder tangible equity for the quarter that ended in Jun. 2026 was $30.26 Mil. Therefore, Orchestra BioMed Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was -314.04%.
The historical rank and industry rank for Orchestra BioMed Holdings's Return-on-Tangible-Equity or its related term are showing as below:
OBIO'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -186.66 Med: -120.84 Max: -81.47
Current: -186.66
During the past 6 years, Orchestra BioMed Holdings's highest Return-on-Tangible-Equity was -81.47%. The lowest was -186.66%. And the median was -120.84%.
OBIO's Return-on-Tangible-Equity is ranked worse than 84.57% of 1199
companies
in the Biotechnology industry
Industry Median: -41.28
vs OBIO: -186.66
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Orchestra BioMed Holdings Return-on-Tangible-Equity Related Terms
Orchestra BioMed Holdings Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Orchestra BioMed Holdings's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OBIO vs CYDY, IRD, VNDA: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Orchestra BioMed Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchestra BioMed Holdings Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Orchestra BioMed Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Orchestra BioMed Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -314.04% mean?
Orchestra BioMed Holdings (OBIO) has a Return-on-Tangible-Equity of -314.04% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Orchestra BioMed Holdings and its competitors. According to the industry distribution chart, Orchestra BioMed Holdings ranks #1014 out of 1199 companies in the Biotechnology industry, placing it in the top 84.6%.
Is Orchestra BioMed Holdings' Return-on-Tangible-Equity too high?
Orchestra BioMed Holdings' current Return-on-Tangible-Equity is -314.04%. Based on the distribution chart, Orchestra BioMed Holdings ranks #1014 out of 1199 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Orchestra BioMed Holdings has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Orchestra BioMed Holdings' Return-on-Tangible-Equity compare to CYDY and IRD?
According to the Biotechnology industry distribution chart, Orchestra BioMed Holdings ranks #1014 out of 1199 companies for Return-on-Tangible-Equity. This places Orchestra BioMed Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Orchestra BioMed Holdings and its competitors. Orchestra BioMed Holdings's current Return-on-Tangible-Equity is -314.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchestra BioMed Holdings stock overvalued right now?
Based on GuruFocus' analysis, Orchestra BioMed Holdings (OBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $31.58, compared to a current price of $5.81 — trading 81.6% below its estimated fair value. The current Return-on-Tangible-Equity is -314.04%. Orchestra BioMed Holdings' overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Orchestra BioMed Holdings (OBIO), the current Return-on-Tangible-Equity is -314.04% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orchestra BioMed Holdings (OBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Orchestra BioMed Holdings stock appears to be undervalued.
The current stock price of $5.81 is trading 81.6% below its estimated GF Value™ of $31.58.
GuruFocus considers Orchestra BioMed Holdings to be Possible Value Trap.
Key valuation signals for OBIO:
Return-on-Tangible-Equity: -314.04%
GF Value™: $31.58 vs. price of $5.81 (81.6% below fair value)
No single metric tells the full story. See the OBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
42GF Score
Get the complete analysis for OBIO
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OBIO has been successfully added to your 
